MYAMBUTOL (ethambutol hydrochloride) by Bayer is clinical pharmacology ethambutol hcl, following a single oral dose of 25 mg/kg of body weight, attains a peak of 2 to 5 mcg/ml in serum 2 to 4 hours after administration. Approved for pulmonary tuberculosis. First approved in 1967.
Drug data last refreshed 18h ago · AI intelligence enriched 21h ago
Myambutol (ethambutol hydrochloride) is an oral small-molecule antimycobacterial agent approved in 1967 for pulmonary tuberculosis. It works by inhibiting mycobacterial cell metabolism and blocking the synthesis of key metabolites, leading to arrest of multiplication and cell death in actively growing Mycobacterium tuberculosis. The drug is typically used as part of combination therapy to prevent resistance to other antituberculous agents like isoniazid.
Minimal spending and claims indicate this is a legacy product with small commercial footprint; career opportunities are limited to maintenance rather than growth-focused roles.
CLINICAL PHARMACOLOGY ETHAMBUTOL HCL, following a single oral dose of 25 mg/kg of body weight, attains a peak of 2 to 5 mcg/mL in serum 2 to 4 hours after administration. When the drug is administered daily for longer periods of time at this dose, serum levels are similar. The serum level of…
Worked on MYAMBUTOL at Bayer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on Myambutol offers minimal career advancement given its legacy status, zero linked job openings, and LOE-approaching lifecycle. Professionals joining this brand would focus primarily on maintaining market access and managing declining revenue rather than strategic growth or innovation.